Stock Region Research Report
🚀 The Momentum & AI Pivot Plays
Stock Region Research Report - Welcome back, Stock Region Family!
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following newsletter is for informational and entertainment purposes only. I am not a licensed financial advisor, and nothing in this email constitutes investment advice, an endorsement, or a recommendation to buy or sell any security. Markets are incredibly volatile, especially in the small-cap and biotech sectors. Always do your own thorough due diligence (DD) and consult with a professional before putting your hard-earned capital at risk.
If you’ve been feeling the market whiplash lately, you aren’t alone. But amidst the noise, there is some serious signal if you know where to look. We’ve been scanning the wire, and this week has delivered a massive slate of clinical breakthroughs, wild earnings beats, and some strategic AI pivots that have my full attention.
Here is the breakdown of what I’m watching and why.
🚀 The Momentum & AI Pivot Plays
When companies pivot into the space economy or double down on AI, the market tends to react aggressively. Here is what is catching my eye:
Digital Turbine ($APPS): This is our Momentum Trade Alert of the week. They delivered a massive double-beat for Q4—posting an EPS of $0.16 (crushing the $0.09 estimate) and $142.55M in revenue. Bank of America just upgraded them to a Buy with a $7.50 price target. At our trigger price of $6.68, there’s a clear 12.3% upside runway. I love seeing a 28.73% return on equity. This one has legs.
Rocket One Inc. ($RKTO) formerly Hoth Therapeutics ($HOTH): This is easily one of the most fascinating pivots I’ve seen all year. Hoth is shedding its biotech skin and rebranding as Rocket One ($RKTO as of May 28) to target the orbital economy. They are pushing next-gen nanomagnetic AI chips for space and defense. It’s a bold move, and given the massive premiums in space-tech right now, I’m watching the tape closely on this ticker transition.
Netcapital ($NCPL) & Asana ($ASAN): Both companies are accelerating their AI footprint through acquisitions. NCPL acquired assets to power up its AI strategy, while ASAN grabbed StackAI to enhance cross-system execution for human-agent teams.
Enhanced ($ENHA): Partnering with Rezolve Ai ($RZLV) in a multi-million dollar deal to build AI-native tech into their live consumer platform.
PRF Technologies ($PRFX): Moving their DeepSolar Predict™ AI platform toward a commercial launch for renewable energy revenue optimization. It popped at $3 after hours—AI plus renewable energy is a narrative combo you can’t ignore.
JFB XTEND ($JFB): Selected for the Phase II Qualifier of the DoD’s $1 Billion Drone Dominance Program. Anytime you see “DoD” and “Billion” in the same sentence, put it on your watchlist.
🧬 Biotech, Health & Clinical Data
The biotech sector is an absolute minefield, but the risk-reward ratio is unparalleled when clinical data hits.
Design Therapeutics ($DSGN): They announced positive Phase 1/2 clinical data for DT-216P2 targeting Friedreich ataxia (FA). It’s a small-molecule therapeutic getting right at the genetic root of the disease. Solid science here, and the market loves disease-modifying therapies.
Lakewood-Amedex ($LABT): Positive data for their lead candidate, Nu-3, treating infected diabetic foot ulcers. Diabetic complications represent a massive total addressable market.
Clearmind Medicine ($CMND): They just signed an agreement to test MEAI in combination with Tirzepatide (a blockbuster GLP-1). Weight-loss drugs are the hottest theme in pharma right now—attaching to this narrative is incredibly smart.
BioLineRx ($BLRX): Dropped new data for GLIX1 showing a potent anti-tumor effect in Glioblastoma (a notoriously difficult brain cancer to treat). Currently sitting around 2.98, this is one of my favorite speculative setups this week.
Autonomix Medical ($AMIX): We saw a volume spike to .45 yesterday after they announced abstract acceptances at EuroPCR 2026 for long-term data in pancreatic cancer pain mitigation. Keep an eye on the volume here.
InMed Pharmaceuticals ($INM): Merging with Mentari Therapeutics to advance migraine prevention. Consolidation in this space is usually a bullish signal for pipeline advancement.
Co-Diagnostics ($CODX): Developing an Ebola assay following a recent global outbreak alert. CODX has historically been highly reactive to global virus headlines.
Polaryx Therapeutics ($PLYX): Closed a $10M private placement to support their Phase 2 basket trial. Cash in hand is king in biotech right now.
Amesite ($AMST): Their NurseMagic™ platform won a 2,700-census home care enterprise customer. That is a massive step-function increase in scale. Proof of execution is everything, and they just proved it.
SPRC: Halted up 11.79 after its subsidiary received conditional regulatory approval to acquire CliniQuantum. The price action here is violent; trade with extreme caution.
Arrive Point ($ARAI) & Wellgistics ($WGRX): ARAI is expanding at Hancock Health after a successful initial deployment, while WGRX announced a lock-up agreement with majority holders, which usually signals insider confidence (or at least prevents immediate dumping).
📊 Earnings & Fundamentals
C3is Inc. ($CISS): Sitting around 3.70, they just reported a staggering 358% increase in Adjusted Net Income for Q1 2026. Fundamentals like that are hard to fake. I am very bullish on this setup.
8x8 ($EGHT): Q4 adjusted EPS of $0.11 beat the $0.08 estimate, and sales of $185.24M beat the $181.12M estimate. A clean, undeniable double-beat.
HIVE Digital ($HIVE): Announced a massive 320 MW Sovereign AI Infrastructure in the Greater Toronto Area. That is a massive scale-up for their high-performance computing capabilities.
GCTS & CREG: Both reported mixed-to-interesting numbers. GCTS missed EPS estimates by 25% but absolutely crushed sales estimates by 9.38% (a 287.10% YoY increase). CREG reported a slight increase in EPS losses but a massive 425% YoY increase in quarterly sales. Both companies are clearly burning cash to capture market share—a high-risk game, but the revenue growth is undeniable.
EZGO Technologies ($EZGO): Signed a three-party framework to build a U.S.-assembled autonomous vehicle platform powered by lithium batteries. I love the “U.S.-assembled” angle here; it circumvents a lot of current geopolitical friction in the EV space.
Disclaimer: Once again, the thoughts and opinions expressed in this newsletter are purely my own and do not represent financial advice. Stock trading involves a high degree of risk, and you can lose some or all of your investment. Please consult with a certified financial planner or advisor before executing any trades based on this information. Stay smart, manage your risk, and happy trading!